Dr. Sanjeev Jain, MD PhD
Dr. Sanjeev Jain was one of the first medical doctors to offer desensitization treatment in private practice, and possibly the first to do combined tree nuts in a single protocol. Educated in allergy and immunology at Yale University, Dr. Jain first received a joint MD and PhD from the University of Wisconsin and finished his residency at the University of Texas. He then taught and practiced at the University of Washington Medical School in Seattle, where he developed a reputation as one of the finest allergists in the region. He has won numerous awards and is included in the Guide to America’s Top Physicians consistently for the last several years.
As an allergist, Dr. Jain treasures the opportunity to witness his patients make dramatic improvements after years of suffering.
He can recall several instances where his patients who had previously required repeated hospital admissions for asthma exacerbations have returned to normal lives free of hospitalizations. In Dr. Jain’s experience, most patients can achieve significant improvements by determining the individual triggers of their allergic reactions and by instituting an appropriate therapy.
Dr. Sanjeev Jain’s LinkedIn Profile
Primary Practice Address:
Columbia Asthma & Allergy Clinic, LLC
1406 SE 164th Street, Suite 250, Vancouver, WA 98683
Phone: 360-940-0810. Website: columbiaallergy.com
Education:
09/1979 – 06/1983 — A.B., Washington University, St. Louis, MO
09/1984 – 08/1990 — M.D., University of Wisconsin- Madison, Madison, WI
09/1983 – 08/1990 — Ph.D., Biochemistry, University of Wisconsin- Madison, Madison, WI
Faculty Positions Held:
08/1990 – 08/1992 — Instructor, Department of Biochemistry, St. Louis University School of Medicine, St. Louis, MO
08/1992 – 08/1995 — Assistant Professor, Department of Biochemistry, St. Louis, University School of Medicine, St. Louis, MO
07/2001 – 06/2005 — Assistant Professor, University of Washington School of Medicine, Seattle, WA
Postgraduate Training:
06/1995 – 06/1998 — Residency, Internal Medicine, University of Texas Health Sciences, Center, San Antonio, TX
06/1998 – 06/2001 — Fellowship, Allergy and Clinical Immunology, Yale University, School of Medicine, New Haven, CT
Hospital Positions Held:
07/2001 – 06/2005 — Staff Physician, University of Washington Medical Center, Department of Medicine, Seattle, WA
10/2005 – 10/2011 & 07/2016 to Present — Staff Physician, Southwest Washington Medical Center, Vancouver, WA
1/2006 – Present — Staff Physician, Legacy Salmon Creek Medical Center, Vancouver, WA
Employment History:
08/1990 – 05/1995 — Faculty, Department of Biochemistry St. Louis University School of Medicine
06/1995 – 06/1998 — Intern/Resident, Internal Medicine, University of Texas Health Science Center, San Antonio, TX
06/1998 – 06/2001 — Fellow, Allergy and Immunology, Yale University School of Medicine, New Haven, CT
07/2001 – 06/2005 — Faculty, Department of Medicine, University of Washington, Seattle, WA
10/2005 – Present — Began Private Practice, Columbia Asthma & Allergy Clinic, LLC, Vancouver, WA
Honors:
1981 — Grass Foundation Scholarship for outstanding undergraduate research in Neurobiology
1987 – 1988 — Peterson Fellowship for outstanding graduate student research in Biochemistry
1988 – 1990 — NIH-Sponsored M.D./Ph.D (MSTP) Program Fellowship
1992 – 1993 — Elsa U. Pardee Foundation Research Grant
1998 – 1999 — American Academy of Allergy, Asthma and Immunology, President’s Award (Schering-Key)
1999 – 2000 — Glaxo Welcome Fellowship in Allergy and Immunology
2000 – 2001 — American Academy of Allergy, Asthma and Immunology, President’s Award (Avantis/Hoechst)
2003 – 2006 — Education Research Trust Faculty Development Award of the American Academy of Allergy, Asthma and Immunology (nationally only one such award is granted annually)
2004 – 2020 — Included in the Guide to America’s Top Physicians
Board Certification:
Internal Medicine — American Board of Internal Medicine certified 1998 to present
Allergy and Immunology — American Board of Allergy and Immunology certified 2001 to present
Current License(s):
Washington — MD00040042
California — G88329
Oregon — MD162938
Professional Memberships:
American Academy of Allergy, Asthma and Immunology
Oregon Society of Allergy, Asthma and Immunology
American Medical Association
American College of Physicians
Clark County Medical Society
Clinical Research Trials:
Phase III: “Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children, Active Treatment Arm” Open–Label Extension Study (RAMSES OLE) ARC-011. (Principal Investigator)
Phase III: Multicenter, North American, open-label, pivotal safety extension study for those subjects who received AR101 therapy in ARC-007 and completed the study. (ARC-008), 2017-2018. (Principal Investigator)
Phase III: A randomized, double-blind, parallel group, multi-center 24-week study comparing the efficacy and safety of three doses of PT001 to placebo and open-label Spiriva Respimat in subjects with persistent asthma (PEARL), 2018-2019. (Sub-Investigator)
Phase III: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two dose levels of BCX7353 as an oral treatment for the prevention of attacks in subjects with Hereditary Angioedema (Study BCX7353-302). (Sub-Investigator)
Phase III: A randomized, Double Dummy, Chronic Dosing (56 week) Placebo-controlled, Parallel Group, Multicenter study to evaluate the efficacy and safety of 3 doses of Benralizumab (MEDI-563) in patients with moderate to very severe Chronic Obstructive Pulmonary Disease (COPD) with a history of COPD exacerbations (TERRANOVA), 2017- Present. (Sub-Investigator)
Phase III: A randomized, multicenter, double-blind, placebo-controlled safety study of AR101 using characterized oral desensitization immunotherapy (CODIT) regimen for approximately 6-months in peanut-allergic children ages 4-17 years (RAMSES), 2017-Present
Phase IIIb: A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the safety and efficacy of Benralizumab (MEDI-563) in patients with severe asthma uncontrolled on standard of care treatment (ANDHI), 2017-July 2019. (Sub-Investigator)
Post-Marketing: A NOVEL observational longitudinal study on patients with a diagnosis or suspected diagnosis of asthma and/or COPD to describe patient characteristics, treatment patterns and the burden of illness over time to identify phenotypes and endotypes associated with differential outcomes that may support future development of personalized treatment strategies (NOVELTY), 2017-Present.
Phase II: Open-label, single arm study to evaluate the safety, immunogenicity, pharmacokinetics and efficacy of recombinant human C1 inhibitor for the treatment of acute attacks in pediatric patients with hereditary angioedema, from 2 up to and including 13 years of age (C1 1209), 2017. (Sub-Investigator)
Phase III: Multi-center, randomized, double-blind, active and placebo-controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Spontaneous Uriticaria (CSU) in adolescents and adults inadequately controlled with H1-antihistamines. (Principal Investigator)
Phase III: Randomized, double-blind, double-dummy, placebo-controlled, parallel group, multi-center study investigating the efficacy and safety of PF-04965842 and Dupilumab in comparison with placebo in adult subjects on background topical therapy, with moderate to severe atopic dermatitis. (Principal Investigator)
Post-Marketing: Observational, non-interventional study of patients with Hereditary Angioedema in the United States and Canada (EMPOWER study). (Sub-Investigator)
Bibliography
- Jain,S., Zon,G., and Sundaralingam,M. 1987. The potentially Z-DNA-forming sequence d(GTGTACAC) crystallizes as A- DNA. J Mol.Biol. 197:141-145.
- Jain,S., Zon,G., and Sundaralingam,M. 1989. Base only binding of spermine in the deep groove of the A-DNA octamer d(GTGTACAC). Biochemistry 28:2360-2364.
- Jain,S. and Sundaralingam,M. 1989. Effect of crystal packing environment on conformation of the DNA duplex. Molecular structure of the A-DNA octamer d(G-T-G-T-A-C-A-C) in two crystal forms. J Biol.Chem. 264:12780-12784.
- Sundaralingam,M., Jain,S., and Zon,G. 1990. Comparison of the molecular structural parameters in the spermine-bound and spermine-free DNA octamer d(GTGTACAC). The conformational plasticity of DNA. Nucleosides and Nucleotides 9:345-348.
- Jain,S., Zon,G., and Sundaralingam,M. 1991. Hexagonal crystal structure of the A-DNA octamer d(GTGTACAC) and its comparison with the tetragonal structure: correlated variations in helical parameters . Biochemistry 30:3567-3576.
- Bingman,C., Jain,S., Zon,G., Sundaralingam,M. Crystal and molecular structure of the alternating dodecamer d (GCGTACGTACGC) in the A-DNA form: comparison with the isomorphous non-alternating dodecamer d(CCGTACGTACGG). Nucleic Acids Res 20:6637-6647.
- Drendel,W.B., Grubb,J.H., Sly,W.S., Chen,Z., Mathews,F.S., and Jain,S. Crystallization and preliminary crystallographic studies of human β-glucuronidase. J Mol.Biol. 233:173-176.
- Drendel,W.B., Dave,R.D., and Jain,S. Forced coalescence phasing: A novel method for ab initio determination of crystallographic phases. Proc.Natl.Acad.Sci.U.S.A 92:547-551.
- Jain,S., Drendel,W.B., Chen,Z.W., Mathews,F.S., Sly,W.S., and Grubb,J.H. 1996. Structure of human beta-glucuronidase reveals candidate lysosomal targeting and active-site motifs. Struct.Biol. 3:375-381.
- Fyfe,J.C., Kurzhals,R.L., Lassaline,M.E., Henthorn,P.S., Alur,P.R., Wang,P., Wolfe,J.H., Giger,U., Haskins,M.E., Patterson,D.F., Sun,H., Jain,S., and Yuhki,N. 1999. Molecular basis of feline beta-glucuronidase deficiency: an animal model of mucopolysaccharidosis VII. Genomics 58:121-128.
- Islam,M.R., Tomatsu,S., Shah,G.N., Grubb,J.H., Jain,S., and Sly,W.S. 1999. Active site residues of human beta-glucuronidase. Evidence for Glu(540) as the nucleophile and Glu(451) as the acid-base residue. J Biol.Chem. 274:23451-23455.
- Klimek-Tomczak, K, Wyrwicz, LS, Jain, S, Bomsztyk, K, and Ostrowski J. 2004. Characterization of hnRNP K protein-RNA interactions. J Mol Biol. 342:1131-1141.
